1 / 5

Dejka Araujo, MD MD Anderson Cancer Center, Houston, TX

A PHASE II TRIAL OF PERIFOSINE IN PATIENTS WITH CHEMO-INSENSITIVE SARCOMAS A SARCOMA ALLIANCE FOR RESEARCH THROUGH COLLABORATION (SARC) STUDY S tudy Update – November 2007. Dejka Araujo, MD MD Anderson Cancer Center, Houston, TX. Patients with < 2 forms of prior chemotherapy stratified by.

armand-hudson
Télécharger la présentation

Dejka Araujo, MD MD Anderson Cancer Center, Houston, TX

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A PHASE II TRIAL OF PERIFOSINE IN PATIENTS WITH CHEMO-INSENSITIVE SARCOMASA SARCOMA ALLIANCE FOR RESEARCH THROUGH COLLABORATION (SARC) STUDYStudy Update – November 2007 Dejka Araujo, MD MD Anderson Cancer Center, Houston, TX

  2. Patients with < 2 forms of prior chemotherapy stratified by Extra-Skeletal Myxoid Chondrosarcoma Alveolar Soft Part Sarcoma Conventional Chondrosarcoma Perifosine 100 mg po qhs daily Evaluate q 12 weeks SD, PR or CR Progression Continue On Study Remove From Study

  3. Objectives Primary • Evaluate the response rate defined by both Choi and RECIST criteria of single agent perifosine Secondary • Evaluate Time to Progression • Evaluate the Clinical Benefit Rate (SD of 6 mo’s or greater)

  4. Major Inclusion / Exclusion Inclusion • Measurable Disease • Documented progression by Choi Criteria • Age > 13 years Exclusion • > 2 prior cytotoxic regimens for metastatic disease (unless exempted)

  5. MD Anderson – 13 Dejka Araujo, MD Penn – 12 Arthur Staddon, MD Sarcoma Oncology – 11 Sant Chawla, MD MSKCC - 8 Robert Maki, MD Michigan - 5 Scott Schuetze, MD Mass General – 5 Edwin Choy, MD Fox Chase – 2 Margaret von Mehren, MD Washington Cancer – 2 Dennis Priebat, MD OHSU – 1 Christopher Ryan, MD Others Open: DFCI, Moffitt, UFL Participants (12) / Enrollment (59) Extra-Skeletal Myxoid Chondrosarcoma - 15 Conventional Chondrosarcoma - 33 Alveolar Soft Part Sarcoma - 11

More Related